Dr. Paul Vincent Viscuse, MD

Dr. Viscuse practices at Emily Couric Clinical Cancer Center in Charlottesville, Virginia.

Dr. Viscuse's NPI, 1053775650, was assigned on April 9, 2016. Dr. Viscuse holds Virginia license 0101274985.

Dr. Viscuse's primary practice is Emily Couric Clinical Cancer Center, at 1240 Lee St,, Charlottesville, VA 22903. The practice phone is (434) 243-4704.

Dr. Viscuse's primary practice is Emily Couric Clinical Cancer Center in Charlottesville, Virginia. Dr. Viscuse is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Viscuse to 1 more hospital and 1 group practice or clinic, each named with a free account. Dr. Viscuse's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Viscuse practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Viscuse's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Viscuse's licenses on file in 2 states: Virginia and Texas.

CMS data shows 664 Medicare services from Dr. Viscuse across 8 procedure codes in 2024, for 163 Medicare patients. Medicare paid $39,412 for them.

CMS counts 163 Medicare patients who saw Dr. Viscuse in 2024. The largest group is 75 to 84, with 75 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Viscuse's median patient age at 69, with 19% women.

In 2024, Dr. Viscuse wrote 391 Medicare Part D claims for 67 patients. 62% of them were for generic drugs. CMS names the drug for 261 of them, across 9 drugs with 11 or more claims each, at $1,620,041 in total drug cost. In 2023, CMS named 97 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Viscuse for performance year 2024, reported as part of a group. Dr. Viscuse accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Viscuse as offering telehealth.

Dmand AI links 24 papers to Dr. Viscuse, published from 2017 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Diagnosis, Differential. Dr. Viscuse has published most often in Cancers (Basel). Dr. Viscuse's most frequent co-authors are Robert Dreicer, MD, Andrew Warren Hahn, MD and Kathryn Jean Ruddy, MD, MPH.

CMS Open Payments shows 36 general payments to Dr. Viscuse from 6 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 51% of the total. Pfizer Inc. paid the most, $6,147.